Molecular Therapy — Nucleic Acids · 2023 · 20 citations · 47 references
Life SciencesGeneticsMolecular BiologyGene ExpressionGenome EditingMolecular VirologyAntiviral TherapyCrispr-based EngineeringCrispr-cas SystemsTherapeutic Genome EditingViral Hepatitis TreatmentVirus-induced Gene SilencingApobec EnzymesClustered Regularly Interspaced Short Palindromic Repeats (Crispr)-based MutagenesisCrispr ActivationCrispr-cas Genome EditingCrispr-cas RegulationCrispr-cas TherapeuticsHbv Dna SuppressionInduced Mutagenesis
APOBEC/AID cytidine deaminases play an important role in innate immunity and antiviral defenses and were shown to suppress hepatitis B virus (HBV) replication by deaminating and destroying the major form of HBV genome, covalently closed circular DNA (cccDNA), without toxicity to the infected cells. However, developing anti-HBV therapeutics based on APOBEC/AID is complicated by the lack of tools for activating and controlling their expression. Here, we developed a CRISPR-activation-based approach (CRISPRa) to induce APOBEC/AID transient overexpression (>4-800,000-fold increase in mRNA levels). Using this new strategy, we were able to control APOBEC/AID expression and monitor their effects on HBV replication, mutation, and cellular toxicity. CRISPRa prominently reduced HBV replication (∼90%-99% decline of viral intermediates), deaminated and destroyed cccDNA, but induced mutagenesis in cancer-related genes. By coupling CRISPRa with attenuated sgRNA technology, we demonstrate that APOBEC/AID activation can be precisely controlled, eliminating off-site mutagenesis in virus-containing cells while preserving prominent antiviral activity. This study untangles the differences in the effects of physiologically expressed APOBEC/AID on HBV replication and cellular genome, provides insights into the molecular mechanisms of HBV cccDNA mutagenesis, repair, and degradation, and, finally, presents a strategy for a tunable control of APOBEC/AID expression and for suppressing HBV replication without toxicity.
47
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
Yanfang Fu, Jennifer A Foden, Cyd Khayter et al. · Nature Biotechnology · 2013 · 3.3K citations · Full text
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities
Traver Hart, Megha Chandrashekhar, Michael Aregger et al. · Cell · 2015 · 1.8K citations · Full text
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore, Ed Gane, Jörg Täubel et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text